DLL3 and neuroendocrine carcinoma: The negative NOTCH regulator delta-like canonical Notch ligand 3 (DLL3) predicted relapse-free survival in STAD and has attracted recent attention as a novel cancer target due to its role in multiple neuroendocrine cancers [50], with the advent of DDL3-targeting agents such as antitumor drug-antibody conjugate Rova-T and AMG-19 [51, 52].